Viridian Therapeutics prelim cash $490.9M as of Sep 30, 2025
Viridian Therapeutics (VRDN) announced a preliminary balance of approximately $490.9 million in cash, cash equivalents, and marketable securities as of September 30, 2025.
Rhea-AI Filing Summary
Viridian Therapeutics (VRDN) announced a preliminary balance of approximately $490.9 million in cash, cash equivalents, and marketable securities as of September 30, 2025. The figure is unaudited and subject to completion of financial closing procedures, and the company’s independent auditor has not performed any review or assurance work on this number. The final amount reported in the upcoming unaudited condensed consolidated balance sheet may differ materially.
Positive
- None.
Negative
- None.
Insights
Preliminary liquidity disclosed: $490.9M as of Q3 end, unaudited.
Viridian Therapeutics provided an early liquidity snapshot of $490.9 million in cash, cash equivalents, and marketable securities as of September 30, 2025. This gives a point-in-time view of resources ahead of final quarterly results.
The company states the figure is preliminary and unaudited, with closing procedures pending and no auditor assurance. The disclosure cautions the number may differ materially once the quarter is finalized.
Without additional operating metrics, this serves as a liquidity indicator only. Subsequent filings will clarify the final balance after closing procedures and any audit review applicable to interim reporting.
8-K Event Classification
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Viridian Therapeutics (VRDN) announce in its 8-K?
Is the $490.9 million cash figure for VRDN audited?
Could Viridian’s reported cash amount change?
What period does VRDN’s preliminary cash balance relate to?
Does the disclosure include earnings or revenue data for VRDN?
What is VRDN’s trading symbol and exchange?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| |
||
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code:
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02 | Results of Operations and Financial Condition. |
On October 21, 2025, the Company announced that while it has not finalized its full financial results for the quarter ended September 30, 2025, the Company expects to report that it had approximately $490.9 million of cash, cash equivalents and marketable securities as of September 30, 2025.
This amount is preliminary, has not been audited and is subject to completion of the Company’s financial closing procedures. The Company’s independent registered public accounting firm has not audited, reviewed, examined, compiled, nor applied agreed-upon procedures with respect to this preliminary information and, accordingly, does not express an opinion or any other form of assurance with respect thereto. Consequently, this amount may differ materially from the amount that will be reflected in the Company’s unaudited condensed consolidated balance sheet as of September 30, 2025.
The information in this Item 2.02 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or under the Securities Act of 1933, as amended, except as expressly provided by specific reference in such filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Viridian Therapeutics, Inc. | ||||||
| Date: October 21, 2025 | By: | /s/ Stephen Mahoney | ||||
| Stephen Mahoney | ||||||
| President and Chief Executive Officer | ||||||